OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Reumabase.it
Ematobase.it

KEYNOTE-427, a single-arm, open-label, phase 2 study, has shown antitumor activity with first-line Pembrolizumab ( Keytruda ) monotherapy in non-clear cell renal cell carcinoma ( nccRCC ) ( cohort B ) ...


TAPUR ( Targeted Agent and Profiling Utilization Registry ) is a phase II basket study evaluating anti-tumor activity of targeted agents in patients with advanced cancers with genomic alterations. R ...


First-line treatment with an EGFR tyrosine kinase inhibitor ( TKI ) is standard of care for patients with EGFR-mutated non-small-cell lung cancer ( NSCLC ). The EGFR TKI Osimertinib ( Tagrisso ) is ...


Cabozantinib ( Cabometyx ) may enhance response to immune checkpoint inhibitors ( ICIs ) by promoting an immune-permissive microenvironment and has shown encouraging activity in combination with ICIs ...


The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple cancers, including non-small-cell lung cancer ( NSCLC ). In a phas ...


The FDA ( U.S. Food and Drug Administration ) has approved Rubraca ( Rucaparib ) tablets for the treatment of adult patients with a deleterious BRCA mutation ( germline and/or somatic )-associated me ...


The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell clusters known as tertiary lymphoid structures ( TLS ), ...


Results from the phase III IMbrave150 study evaluating Atezolizumab ( Tecentriq ) in combination with Bevacizumab ( Avastin ) were presented. The data have shown statistically significant and clinic ...


Sorafenib ( Nexavar ) is approved as first-line therapy for patients with advanced hepatocellular carcinoma ( HCC ), but there is still an unmet need to prolong survival and improve tolerability. A ...


The triplet combination of the BRAF inhibitor, Encorafenib ( Braftovi ), MEK inhibitor, Binimetinib ( Mektovi ), and EGFR inhibitor, Cetuximab ( Erbitux ), not only has significantly improved overall ...


Over 60% of patients with stage IV melanoma may develop brain metastases, resulting in a significantly increased morbidity and poor overall prognosis. Clinical data for melanoma brain metastases ( M ...


The first-line treatment with Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has demonstrated improvements in overall survival ( OS ), progression-free survival ( P ...


Hyperprogressive disease ( HPD ) is a paradoxical boost in tumour growth described in a subset of cancer patients treated with immune checkpoint inhibitors ( ICIs ). Researchers retrospectively col ...


Positive results from the phase 3 PAOLA-1 trial in women with advanced ovarian cancer. were announced. The trial, in the first-line maintenance setting, compared Olaparib ( Lynparza ) added to stand ...


Detailed results from the phase III CASPIAN trial were presented at IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain. ...